VK2735 for Obesity

Recruiting at 14 trial locations

Overseen ByStephanie Herman

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Viking Therapeutics, Inc.

Must not be taking: GLP-1 agonists, Weight loss meds

Disqualifiers: Diabetes, Chronic pancreatitis, others

Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.VK2735 or matched placebo will be administered once daily.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot have used any GLP-1 receptor agonists or weight loss medications within 6 months before the screening.

Are You a Good Fit for This Trial?

This trial is for adults who are obese with a BMI of 30 or higher, or overweight with a BMI of at least 27 and have one weight-related health issue. Key eligibility details aren't provided, so interested individuals should inquire further about specific inclusion and exclusion criteria.

Inclusion Criteria

My BMI is between 27 and 50, and I may have a condition like high blood pressure or sleep apnea.

Exclusion Criteria

I have been diagnosed with diabetes.

I have been diagnosed with chronic pancreatitis.

I haven't taken any GLP-1 drugs in the last 6 months.

See 4 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive VK2735 or placebo daily for weight management over 13 weeks

13 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

VK2735

Trial Overview The study tests VK2735 against a placebo to see if it helps with weight loss. Participants will be randomly assigned to receive either the drug or placebo once daily for 13 weeks in this double-blind study where neither they nor the researchers know who gets what.

How Is the Trial Designed?

7Treatment groups

Experimental Treatment

Placebo Group

Group I: Active Assignment (Dose #6)Experimental Treatment1 Intervention